Business
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on
About this update from Nuvectis Pharma, Inc.
[{"type":"text","content":"Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, today provided highlights from the poster presentation of NXP900 that took place yesterday at the American Association for Cancer Research (“AACR”) Conference in New Orleans. “A growing body of scientific evidence provides exciting development opportunities for NXP900\" said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. “NXP900 is a very potent and selective SRC/YES1 inhibitor with a unique mechanism of action that inhibits both the catalytic and scaffolding functions of the target kinases. Yesterday’s poster presentation demonstrated for the first time the potency of NXP900 against various cancer cells of squamous origin, and together with the previously reported preclinical activity of NXP900 in xenograft models of triple-negative breast cancer (TNBC), as well as the recent publication from the R&D group at AstraZeneca in Nature Communication that demonstrated the ability of NXP900 to re-sensitize Tagrisso-resistant non-small cell lung cancer (NSCLC) cells to Tagrisso, the bank of potential indications for NXP900 continues to grow. We look forward to completing the IND-enabling studies this year and plan to initiate the clinical program shortly thereafter.” NXP900 Poster Presentation Key Highlights Novel mechanism of action locks the target kinase in its closed confirmation, resulting in inhibition of both the catalytic and scaffolding functions ot the target.High selectivity demonstrated in a comprehensive kinome screenClinically relevant mechanisms of sensitivity identified High sensitivity in various types of cancer cell lines of squamous origin (cancers originating from squamous cells are prevalent in lung, head & neck, cervical, skin and esophageal malignancies).FAT1 loss-of-function mutations, which are highly prevalent in squamous carcinomas, in particular in head & neck, is associated with sensitivity to NXP900 IND-enabling studies ongoing About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. The Company is cur...